DeepMed Research

Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Morbid Rates After Spiriva Chronic Obstructive Pulmonary Disease (COPD) Protocol Change

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

First Posted Date: 2023-09-25

Last Posted Date: 2024-10-26

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 3015000

Registration Number: NCT06053541

Locations: 🇧🇷
Boehringer Ingelheim Brasil, São Paulo, Brazil

A Study in Healthy Men to Test Whether Itraconazole Influences the Amount of BI 1584862 in the Blood

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1584862
Drug: itraconazole

First Posted Date: 2023-09-18

Last Posted Date: 2023-11-28

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 14

Registration Number: NCT06041438

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

A Study in Healthy Men to Test Whether Carbamazepine Influences the Amount of BI 1810631 in the Blood

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1810631
Drug: Carbamazepine

First Posted Date: 2023-09-08

Last Posted Date: 2024-10-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 16

Registration Number: NCT06028464

Locations: 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany

A Study to Test Whether Spesolimab Helps People With Generalized Pustular Psoriasis (GPP) Who Need Treatment for Repeated Flares

Phase 4

Active, not recruiting

Conditions: Generalized Pustular Psoriasis

Interventions: Drug: Spesolimab

First Posted Date: 2023-08-28

Last Posted Date: 2025-04-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 42

Registration Number: NCT06013969

Locations: 🇲🇾
Hospital Kuala Lumpur, Kuala Lumpur, Malaysia
🇲🇾
Hospital Putrajaya, Putrajaya, Malaysia
🇲🇾
Sunway Medical Centre, Selangor Darul Ehsan, Malaysia

and more 30 locations

A Study to Test How Well Different Doses of BI 1584862 Are Tolerated by Healthy Men

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1584862
Drug: Placebo matching BI 1584862
Drug: midazolam

First Posted Date: 2023-08-23

Last Posted Date: 2024-05-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 50

Registration Number: NCT06006598

Locations: 🇩🇪
Charité Research Organisation GmbH, Berlin, Germany

A Study to Test How Well Different Doses of BI 771716 Are Tolerated by People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy

Phase 1

Completed

Conditions: Geographic Atrophy

Interventions: Drug: BI 771716

First Posted Date: 2023-08-23

Last Posted Date: 2025-02-18

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 20

Registration Number: NCT06006585

Locations: 🇺🇸
Retina Consultants of Houston, PA-Houston-62050, Houston, Texas, United States
🇺🇸
Retina Consultants of Texas-The Woodlands-67575, The Woodlands, Texas, United States
🇺🇸
Bay Area Retina Associates - Walnut Creek, Walnut Creek, California, United States

and more 6 locations

DAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With Topotecan

Phase 1

Recruiting

Conditions: Small Cell Lung Carcinoma (SCLC)

Interventions: Drug: BI 764532
Drug: Topotecan
Drug: Single agent chemotherapy

First Posted Date: 2023-08-14

Last Posted Date: 2025-04-30

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 90

Registration Number: NCT05990738

Locations: 🇺🇸
Mayo Clinic - Florida, Jacksonville, Florida, United States
🇺🇸
University of Miami, Miami, Florida, United States
🇫🇷
INS Curie, Paris, France

and more 9 locations

A Study in Healthy People to Test How Well Repeated Doses of BI 3032950 Are Tolerated

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 3032950
Drug: Placebo matching BI 3032950

First Posted Date: 2023-08-14

Last Posted Date: 2024-11-21

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 40

Registration Number: NCT05985200

Locations: 🇧🇪
SGS Life Science Services - Clinical Research, Edegem, Belgium

A Study to Test How Well Different Doses of BI 3006337 Are Tolerated by People With Overweight or Obesity and With Fatty Liver Disease

Phase 1

Completed

Conditions: Non-alcoholic Fatty Liver Disease
Obesity

Interventions: Drug: BI 3006337
Drug: Placebo matching BI 3006337

First Posted Date: 2023-08-01

Last Posted Date: 2025-03-18

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 64

Registration Number: NCT05970640

Locations: 🇺🇸
Velocity Clinical Research-Chula Vista-67286, Chula Vista, California, United States
🇺🇸
Velocity Clinical Research-La Mesa-69117, La Mesa, California, United States
🇺🇸
Catalina Research Institute, LLC-Montclair-49051, Montclair, California, United States

and more 9 locations

Describing Patient With DME, Their Patient Journey and Disease Progression

Completed

Conditions: Diabetic Macular Edema

First Posted Date: 2023-08-01

Last Posted Date: 2024-12-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 221004

Registration Number: NCT05966753

Locations: 🇺🇸
CorEvitas HQ, Waltham, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy